Melanoma Drugs Market Revenue, Emerging Key Players, Supply-Demand Melanoma Drugs | Page 5

10.7.2.1 Chemotherapy
10.7.2.2 Immunotherapy
10.7.3 Pfizer, Sanofi Melanoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
10.7.4 Main Business/Business Overview
10.8 Takeda Pharmaceutical Company Limited
10.8.1 Company Basic Information, Manufacturing Base and Competitors
10.8.2 Melanoma Drugs Product Type, Application and Specification
10.8.2.1 Chemotherapy
10.8.2.2 Immunotherapy
10.8.3 Takeda Pharmaceutical Company Limited Melanoma Drugs Sales, Revenue, Price and Gross
Margin (2012-2017)
10.8.4 Main Business/Business Overview
10.9 Teva Pharmaceuticals
10.9.1 Company Basic Information, Manufacturing Base and Competitors
10.9.2 Melanoma Drugs Product Type, Application and Specification
10.9.2.1 Chemotherapy
10.9.2.2 Immunotherapy
10.9.3 Teva Pharmaceuticals Melanoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
10.9.4 Main Business/Business Overview
11 Melanoma Drugs Manufacturing Cost Analysis
11.1 Melanoma Drugs Key Raw Materials Analysis
11.1.1 Key Raw Materials
11.1.2 Price Trend of Key Raw Materials
11.1.3 Key Suppliers of Raw Materials
11.1.4 Market Concentration Rate of Raw Materials
11.2 Proportion of Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Manufacturing Process Analysis of Melanoma Drugs
12 Industrial Chain, Sourcing Strategy and Downstream Buyers
12.1 Melanoma Drugs Industrial Chain Analysis
12.2 Upstream Raw Materials Sourcing
12.3 Raw Materials Sources of Melanoma Drugs Major Manufacturers in 2015
12.4 Downstream Buyers
13 Marketing Strategy Analysis, Distributors/Traders
13.1 Marketing Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Development Trend
13.2 Market Positioning
13.2.1 Pricing Strategy
13.2.2 Brand Strategy
13.2.3 Target Client
13.3 Distributors/Traders List
14 Europe Melanoma Drugs Market Forecast (2017-2022)